\
&
Contact us
\
&
Contact us
Pick a topic from the menu to get started.
This video will take you through the basics of proposal writing under Pillar II of the Horizon Europe programme (with focus on Research and Innovation Actions / Innovation Actions).
These materials are intended for personal use and viewing. Please don't copy or circulate without asking permission.
DISCLAIMER -The information in this presentation is intended to support the writing of a project proposals under Pillar II of Horizon Europe. Effort has been made to ensure that the information contained in this document is accurate and up to date. Please always check the latest version of Commission documents for the most up-to-date information. NCP Flanders does not assume any liability or responsibility for the completeness, accuracy, or usefulness of the information included in this presentation.
Pick a topic from the menu to get started.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
